After Amylyx Pharmaceuticals announced the price of its recently approved amyotrophic lateral sclerosis treatment, the drugmaker’s co-CEOs told Politico why it costs $158,000 for one patient’s annual supply.
Read the full post on Becker's Hospital Review - Healthcare News
